Flow of Patients Through Trial

Slides:

Advertisements

Similar presentations

STRADIVARIUS Effect of Rimonabant on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Stephen J. Nicholls.

Advertisements

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.

Trial profile Fox K et al. Lancet 2008;372:

Weng TC, et al. J Clin Pharm Ther 2010;35:

A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.

Philip J. Barter, et al. Circulation 2011;124:

Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects: SATURN Study Results SJ Nicholls,

Flow Diagram of the Main HOPE Trial and the HOPE-TOO Trial Extension The HOPE and HOPE-TOO Trial Investigators JAMA. 2005;293:

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

A Diabetes Outcome Progression Trial

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

PERISCOPE Comparison of Pioglitazone vs. Glimepiride on Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes Stephen J. Nicholls MBBS.

for The STRADIVARIUS Investigators

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Slide Source: Lipids Online Slide Library Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Nissen SE et al. JAMA.

Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

The SPRINT Research Group

The American College of Cardiology Presented by Dr. Steven E. Nissen

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Neal B, et al. Diabetes Care 2015;38:403–411

HbA1c 1245_0025final study-report-body. Table : 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD)

ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.

Supplementary material

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

End point Rimonabant 20 mg (n=339) Placebo (n=348) p Weight (kg) -5.3

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Prehypertension, Diabetes, and Cardiovascular Disease Risk in a Population-Based Sample by Ying Zhang, Elisa T. Lee, Richard B. Devereux, Jeunliang Yeh,

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Robert W. Yeh et al. JACC 2017;70:

Placebo group 5-mg rimonabant group p 20-mg rimonabant group

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Daan Kromhout, et al. NEJM epub August 29, 2010

Flow of Patients Through the Trial

Characteristics of the Patients at Baseline*

Trial profile Luc F Van Gaal, Lancet 2005;365:1389.

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Study Participant Flow

Scatterplot showing the association between change in HbA1c at 1 year and weight change at 1 year, relative to baseline for each treatment group. Scatterplot.

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Disposition of Patients in the Atherogenic Dyslipidemia Study

Baseline Characteristics by hs-CRP

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Pramlintide Therapy Part 1of 2

Change in markers of glycometabolism and cardiovascular risk profile.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Effect of empagliflozin on efficacy parameters at week 18.

© The Author(s) Published by Science and Education Publishing.

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

Presentation transcript:

Flow of Patients Through Trial Nissen SE, et al. JAMA 2008;299:1547-60

Baseline Characteristics of the Study Population (n=839)a Nissen SE, et al. JAMA 2008;299:1547-60

Body Weight, Waist Circumference, Metabolic Outcomes, and Blood Pressure in Patients Completing the Trial (n=676)a Nissen SE, et al. JAMA 2008;299:1547-60

Effects of Rimonabant on Body Weight, Waist Circumference, and Levels of HDL-C, Triglycerides, Fasting Insulin, and Glycated Hemoglobin (HbA1c) Nissen SE, et al. JAMA 2008;299:1547-60

Baseline, Follow-up, and Change from Baseline in Intravascular Ultrasound End Points in Patients Completing the Trial (n = 676) Nissen SE, et al. JAMA 2008;299:1547-60

Primary Efficacy Parameter (Percent Atheroma Volume) in Subgroups Nissen SE, et al. JAMA 2008;299:1547-60

Major Cardiovascular Adverse Events, Treatment-Emergent Adverse Events, and Reasons for Study Drug Discontinuation (Randomized Population, n=839) Nissen SE, et al. JAMA 2008;299:1547-60

Cumulative Incidence of Drug Discontinuation Nissen SE, et al. JAMA 2008;299:1547-60